Specify a stock or a cryptocurrency in the search bar to get a summary
Epigenomics AG
EPGNFEpigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. The company was founded in 1998 and is headquartered in Berlin, Germany. Address: Geneststrasse 5, Berlin, Germany, 10829
Analytics
WallStreet Target Price
8.59 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures EPGNF
Dividend Analytics EPGNF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EPGNF
Stock Valuation EPGNF
Financials EPGNF
Results | 2019 | Dynamics |